Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [Y78] to MEK2 (HRP)
- Suitable for: WB
- Knockout validated
- Reacts with: Human
- Conjugation: HRP
Product nameAnti-MEK2 antibody [Y78] (HRP)
See all MEK2 primary antibodies
DescriptionRabbit monoclonal [Y78] to MEK2 (HRP)
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse
Synthetic peptide. within Human MEK2 aa 1 to the C-terminus (N terminal). The exact sequence is proprietary.
Database link: P36507
- WB: Jurkat whole cell lysate.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: PBS, 30% Glycerol, 1% BSA
Concentration information loading...
PurityProtein A purified
- Anti-MEK2 antibody [Y78] (Alexa Fluor® 647) (ab200519)
- Anti-MEK2 antibody [Y78] (Alexa Fluor® 488) (ab200606)
- Anti-MEK2 antibody [Y78] (PE) (ab213661)
- Anti-MEK2 antibody [Y78] (Alexa Fluor® 555) (ab214633)
- Anti-MEK2 antibody [Y78] (Alexa Fluor® 594) (ab214845)
- Anti-MEK2 antibody [Y78] - BSA and Azide free (ab233731)
- Anti-MEK2 antibody [Y78] (ab32517)
Our Abpromise guarantee covers the use of ab200607 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/7500. Detects a band of approximately 45 kDa (predicted molecular weight: 44 kDa).|
FunctionCatalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases.
Involvement in diseaseDefects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
Sequence similaritiesBelongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
Contains 1 protein kinase domain.
modificationsMAPKK is itself dependent on Ser/Thr phosphorylation for activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).
Acetylation of Ser-222 and Ser-226 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
- Information by UniProt
- Cardiofaciocutaneous syndrome antibody
- CFC syndrome antibody
- CFC4 antibody
All lanes : Anti-MEK2 antibody [Y78] (HRP) (ab200607) at 1/7500 dilution
Lane 1 : Wild-type HAP1 whole cell lysate
Lane 2 : MAP2K2 (MEK2) knockout HAP1 whole cell lysate
Lysates/proteins at 20 µg per lane.
Predicted band size: 44 kDa
Observed band size: 44 kDa
Exposure time: 30 seconds
ab200607 was shown to specifically react with MEK2 in wild-type HAP1 cells as signal was lost in MAP2K2 (MEK2) knockout cells. Wild-type and MAP2K2 (MEK2) knockout samples were subjected to SDS-PAGE. Ab200607 and ab184095 (Mouse monoclonal [mAbcam 9484] to GAPDH - Loading Control (Alexa Fluor® 680) loading control) were incubated overnight at 4°C at 1/7500 dilution and 1/1000 dilution respectively. The loading control was imaged using the Licor Odyssey CLx prior to blots being developed with ECL technique.
Anti-MEK2 antibody [Y78] (HRP) (ab200607) at 1/7500 dilution + Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 44 kDa
Observed band size: 45 kDa why is the actual band size different from the predicted?
Additional bands at: 100 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 10 seconds
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab200607 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab200607 has not yet been referenced specifically in any publications.